{'fraction_non_alphanumeric': 0.021937842778793418, 'fraction_numerical': 0.013711151736745886, 'mean_word_length': 5.257142857142857, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Naftidrofuryl in the treatment of simple diabetic retinopathy. A double-blind study].

During a randomized double-blind study 23 patients with nonproliferative diabetic retinopathy were treated orally with 600 mg Naftidrofuryl daily for six months, while 25 patients served as control group. Measurements of visual acuity and fundus photography were performed before and after 3 and 6 months of observation. Measurement of visual acuity showed a significant deterioration in the functional state of eyes in the control group. This deterioration was clearly less pronounced in the treated group, though not statistically significant. There was no significant change in the amount of exudation in either group. In contrast, retinal bleeding and the number of microaneurysms increased significantly both within the control group as well as compared with the treated group (p less than 0.05). This progression was checked to a significant extent in the treated group. Thus, the overall assessment of therapy indicated that Naftidrofuryl treatment brought significant advantages (p less than 0.05).